1Miller M, Cosgrove B, Havas S. Update on the role of triglycerides as a risk factor for coronary heart disease[J].Curr Atheroscler Rep, 2002, 4(6) :414 - 418.
2Instull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial[ J ]. Mayo Clin Proc, 2001, 76(10) :971 - 982.
3Weston C. The place of ezetimibe in clinical practice[J].Hosp Med, 2003, 64(8) :473 -478.
4Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia[J]. Am J Cardiol, 2003, 91 (4):418 -424.
5Stein EA. An investigative look: selective cholesterol absorption inhibitors - embarking on a new standard of care[J]. Am L Manag Care, 2002, 8(2 Suppl):S36 - S39.
6Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia[ J]. Am Heart J, 2002,144(6): 1044 - 1051.
7Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers[ J]. Br J Clin Pharmacol, 2002,54(5) :472 - 477.
8Saito Y, Yamada N, Teramoto T, et al. A randomized,double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia[ J ]. Atherosclerosis, 2002, 162 (2):373 - 379.
9Aoki T, Yamazaki H, Tamaki T, et al. Triglyceride-lowering effect of pitavastatin in a guinea pig model of postprandial lipemia[J]. Arzneimittelforschung, 2003, 53(3):154-158.
10Bolego C, Poli A, Cignarella A, et al. Novel statins: pharmacolngical and clinical results[J]. Cardiovasc Drugs Ther,2002, 16(3) :251 - 257.
